Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other financing activities (2021 - 2026)

Cytek Biosciences filings provide 5 years of Other financing activities readings, the most recent being $268000.0 for Q4 2025.

  • On a quarterly basis, Other financing activities rose 106.15% to $268000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $670000.0, a 20.94% increase, with the full-year FY2025 number at $670000.0, up 20.94% from a year prior.
  • Other financing activities hit $268000.0 in Q4 2025 for Cytek Biosciences, up from $171000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $268000.0 in Q4 2025 to a low of -$1.1 million in Q3 2021.
  • Median Other financing activities over the past 5 years was $120000.0 (2023), compared with a mean of $48187.5.
  • Biggest five-year swings in Other financing activities: skyrocketed 159.65% in 2024 and later fell 21.54% in 2025.
  • Cytek Biosciences' Other financing activities stood at -$1.1 million in 2021, then soared by 106.57% to $71000.0 in 2022, then skyrocketed by 43.66% to $102000.0 in 2023, then grew by 27.45% to $130000.0 in 2024, then surged by 106.15% to $268000.0 in 2025.
  • The last three reported values for Other financing activities were $268000.0 (Q4 2025), $171000.0 (Q3 2025), and $102000.0 (Q2 2025) per Business Quant data.